BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 25421221)

  • 1. Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry.
    Hulegårdh E; Nilsson C; Lazarevic V; Garelius H; Antunovic P; Rangert Derolf Å; Möllgård L; Uggla B; Wennström L; Wahlin A; Höglund M; Juliusson G; Stockelberg D; Lehmann S
    Am J Hematol; 2015 Mar; 90(3):208-14. PubMed ID: 25421221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study.
    Granfeldt Østgård LS; Medeiros BC; Sengeløv H; Nørgaard M; Andersen MK; Dufva IH; Friis LS; Kjeldsen E; Marcher CW; Preiss B; Severinsen M; Nørgaard JM
    J Clin Oncol; 2015 Nov; 33(31):3641-9. PubMed ID: 26304885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia?
    Larson RA
    Best Pract Res Clin Haematol; 2007 Mar; 20(1):29-37. PubMed ID: 17336252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive factors for latency period and a prognostic model for survival in patients with therapy-related acute myeloid leukemia.
    Ornstein MC; Mukherjee S; Mohan S; Elson P; Tiu RV; Saunthararajah Y; Kendeigh C; Advani A; Kalaycio M; Maciejewski JP; Sekeres MA
    Am J Hematol; 2014 Feb; 89(2):168-73. PubMed ID: 24123154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Older patients with acute myeloid leukemia benefit from intensive chemotherapy: an update from the Swedish Acute Leukemia Registry.
    Juliusson G
    Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S54-9. PubMed ID: 22035749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognosis of older patients with acute myeloid leukemia receiving either induction or noncurative treatment: a single-center retrospective study.
    Behringer B; Pitako JA; Kunzmann R; Schmoor C; Behringer D; Mertelsmann R; Lübbert M
    Ann Hematol; 2003 Jul; 82(7):381-9. PubMed ID: 12756497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Failure matters: unsuccessful cytogenetics and unperformed cytogenetics are associated with a poor prognosis in a population-based series of acute myeloid leukaemia.
    Lazarevic V; Hörstedt AS; Johansson B; Antunovic P; Billström R; Derolf Å; Lehmann S; Möllgård L; Peterson S; Stockelberg D; Uggla B; Vennström L; Wahlin A; Höglund M; Juliusson G
    Eur J Haematol; 2015 May; 94(5):419-23. PubMed ID: 25200361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved outcome in acute myeloid leukemia patients enrolled in clinical trials: A national population-based cohort study of Danish intensive chemotherapy patients.
    Østgård LS; Nørgaard M; Sengeløv H; Medeiros BC; Kjeldsen L; Overgaard UM; Severinsen MT; Marcher CW; Jensen MK; Nørgaard JM
    Oncotarget; 2016 Nov; 7(44):72044-72056. PubMed ID: 27732947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Translocation t(9;11)(p21;q23) in pediatric de novo and secondary acute myeloblastic leukemia.
    Sandoval C; Head DR; Mirro J; Behm FG; Ayers GD; Raimondi SC
    Leukemia; 1992 Jun; 6(6):513-9. PubMed ID: 1602790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reasons for treating secondary AML as de novo AML.
    Ostgård LS; Kjeldsen E; Holm MS; Brown Pde N; Pedersen BB; Bendix K; Johansen P; Kristensen JS; Nørgaard JM
    Eur J Haematol; 2010 Sep; 85(3):217-26. PubMed ID: 20456491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML.
    Schoch C; Kern W; Schnittger S; Hiddemann W; Haferlach T
    Leukemia; 2004 Jan; 18(1):120-5. PubMed ID: 14586477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival difference between secondary and de novo acute myeloid leukemia by age, antecedent cancer types, and chemotherapy receipt.
    Sedeta E; Jemal A; Nisotel L; Sung H
    Cancer; 2024 Jun; 130(11):1952-1963. PubMed ID: 38244208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pediatric therapy-related myelodysplastic syndrome/acute myeloid leukemia: the MD Anderson Cancer Center experience.
    Aguilera DG; Vaklavas C; Tsimberidou AM; Wen S; Medeiros LJ; Corey SJ
    J Pediatr Hematol Oncol; 2009 Nov; 31(11):803-11. PubMed ID: 19801947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elderly Patients (Age 70 Years or Older) With Secondary Acute Myeloid Leukemia or Acute Myeloid Leukemia Developed Concurrently to Another Malignant Disease.
    Collinge E; Loron S; Larcher MV; Elhamri M; Heiblig M; Deloire A; Ducastelle S; Labussière H; Barraco F; Wattel E; Salles G; Paubelle E; Thomas X
    Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):e211-e218. PubMed ID: 29572159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hematopoietic stem cell transplantation rates and long-term survival in acute myeloid and lymphoblastic leukemia: real-world population-based data from the Swedish Acute Leukemia Registry 1997-2006.
    Juliusson G; Karlsson K; Lazarevic VLj; Wahlin A; Brune M; Antunovic P; Derolf A; Hägglund H; Karbach H; Lehmann S; Möllgård L; Stockelberg D; Hallböök H; Höglund M;
    Cancer; 2011 Sep; 117(18):4238-46. PubMed ID: 21387283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly patients with de novo acute myeloid leukemia: a report from the GOELAMS.
    Pigneux A; Harousseau JL; Witz F; Sauvezie M; Bene MC; Luquet I; Hunault-Berger M; Recher C; Lioure B; Himberlin C; Escoffre-Barbe M; Berthou C; Lissandre S; Fegueux N; Cahn JY; Jourdan E; Dreyfus F; Reiffers J; Milpied N; Ifrah N
    J Clin Oncol; 2010 Jun; 28(18):3028-34. PubMed ID: 20479424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Should patients over 65 years old with acute myeloid leukemia be treated with myelosuppressive chemotherapy?].
    Spataro V; Cometta A; Glauser MP; Schapira M; Grob JP
    Schweiz Med Wochenschr; 1995 Mar; 125(9):429-32. PubMed ID: 7892571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studies.
    Oosterveld M; Suciu S; Muus P; Germing U; Delforge M; Belhabri A; Aul C; Selleslag D; Ferrant A; Marie JP; Amadori S; Jehn U; Mandelli F; Hess U; Hellström-Lindberg E; Cakmak-Wollgast S; Vignetti M; Labar B; Willemze R; de Witte T
    Ann Hematol; 2015 Jan; 94(1):23-34. PubMed ID: 25096636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multilineage dysplasia is associated with a poorer prognosis in patients with de novo acute myeloid leukemia with intermediate-risk cytogenetics and wild-type NPM1.
    Rozman M; Navarro JT; Arenillas L; Aventín A; Giménez T; Alonso E; Perea G; Camós M; Navarrete M; Tuset E; Florensa L; Millá F; Nomdedéu J; de la Banda E; Díaz-Beyá M; Pratcorona M; Garrido A; Navarro B; Brunet S; Sierra J; Esteve J;
    Ann Hematol; 2014 Oct; 93(10):1695-703. PubMed ID: 24824767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic alteration patterns and clinical outcomes of elderly and secondary acute myeloid leukemia.
    Wang SY; Cheng WY; Mao YF; Zhu YM; Liu FJ; Ma TT; Shen Y
    Hematol Oncol; 2019 Oct; 37(4):456-463. PubMed ID: 31348835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.